Clinical trials are available for patients with an isocitrate dehydrogenase (IDH) mutation with hematologic malignancies and solid tumors

Committed to research

Inspired by patients and frustrated by the limitations of conventional approaches to cancer treatment, Agios is forging a new and different path to treating cancer by targeting cellular metabolism. Agios is committed to researching the role of IDH in cancer.

For more information about our clinical development programs, visit agios.com/pipeline/overview/.
Learn about cancer clinical trials for patients with IDH mutations

Contact Agios Medical Affairs to learn more about Agios-sponsored clinical trials.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 1-833-228-8474

Keep Me Informed

Receive the latest information about IDH mutations and their role in cancer from Agios.
This information is intended for healthcare professionals.



*Required fields

I would like to receive future communications about IDH mutations from Agios focused on (select one or more):